Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Advances IL-23, Gastroenterology Ambitions With Mirikizumab In Crohn's Disease

Executive Summary

The company reported positive Phase II results and will move its potential fourth-to-market IL-23 inhibitor into Phase III in Crohn's disease later this year. Mirikizumab – in Phase III for psoriasis and ulcerative colitis – may be the second IL-23 drug for an IBD indication.

Advertisement

Related Content

In Immunology, J&J Makes A Big Move On Biologic Combinations
AbbVie’s Humira Succession Plan Begins Taking Shape With Skyrizi US Approval
Pfizer's Xeljanz Pushed By New Tailwind From Approval In Ulcerative Colitis
New Crohn’s Indication Puts Janssen’s Stelara On Equal Ground With Anti-TNFs

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC125263

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel